Testing effectiveness (Phase 2)Study completedNCT02289950
What this trial is testing
Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Who this might be right for
Platinum-Sensitive Ovarian Cancer in First Relapse
Eisai Inc. 332